YMR001C-A Antibody

What is YMR001C-A and what cellular function does this protein serve in yeast?

YMR001C-A is a gene in Saccharomyces cerevisiae (strain ATCC 204508 / S288c), commonly known as baker's yeast, that encodes a hypothetical protein. The gene is located on chromosome XIII of S. cerevisiae . This protein (UniProt accession number Q8TGS9) has been identified through genomic sequencing but its precise function remains largely uncharacterized .

In yeast genetics, genes with the "YMR" prefix indicate their location on chromosome XIII, with the subsequent numbers and letters providing information about their specific position and orientation. The "C" in YMR001C-A indicates that this gene is encoded on the complementary strand (i.e., it's transcribed in the reverse direction) .

While the exact function of this hypothetical protein remains to be fully elucidated, many such proteins identified through genomic sequencing are now being studied for potential roles in cellular processes including metabolism, stress response, or cell cycle regulation in yeast .

What are the recommended validation methods for confirming YMR001C-A Antibody specificity?

For validating YMR001C-A antibody specificity, researchers should implement a multi-pillar approach in accordance with the International Working Group on Antibody Validation (IWGAV) guidelines . Since YMR001C-A is a yeast protein, the following validation methods are particularly relevant:

Genetic validation strategy: This is the gold standard approach. Researchers should:

• Perform Western blot analysis comparing wild-type yeast with YMR001C-A knockout strains

• The antibody signal should be present in wild-type samples but absent in the knockout

Independent antibody strategy:

• Use two or more antibodies that recognize different epitopes of YMR001C-A

• Consistent detection patterns between antibodies suggest specificity

Orthogonal validation:

• Compare antibody detection with non-antibody methods like mass spectrometry

• Positive correlation between detection methods strengthens validation

Expression of tagged proteins:

• Generate yeast strains expressing YMR001C-A with epitope tags (e.g., FLAG, HA)

• Compare detection patterns between anti-tag antibodies and YMR001C-A antibodies

Cross-reactivity testing:

• Test the antibody against closely related yeast proteins to ensure specificity

• Especially important for polyclonal antibodies which may recognize multiple epitopes

What controls should I include when using YMR001C-A Antibody in experimental workflows?

Proper experimental controls are essential for interpreting results with YMR001C-A Antibody:

For genetic validation studies, it's particularly important to include YMR001C-A knockout strains created using CRISPR/Cas9 or other gene editing techniques . When using tagged YMR001C-A constructs, both anti-tag antibodies and YMR001C-A-specific antibodies should be used in parallel to confirm specificity .

For co-immunoprecipitation experiments, include a pre-clear step with non-immune serum or IgG to reduce non-specific binding, and perform reverse immunoprecipitation to validate protein interactions .

How do native versus denatured conditions affect YMR001C-A Antibody performance in different applications?

The performance of YMR001C-A Antibody varies significantly between native and denatured conditions, affecting experimental design choices:

Native conditions (non-denaturing):

• Most suitable for: Immunoprecipitation, flow cytometry, ELISA, ChIP

• Epitope recognition: The antibody recognizes the three-dimensional structure of the protein

• Buffer considerations: Gentle lysis buffers (e.g., RIPA without SDS) preserve protein structure

• Advantages: Allows detection of protein-protein interactions and functional studies

• Limitations: Lower sensitivity for detecting low-abundance proteins

Denatured conditions:

• Most suitable for: Western blotting, immunohistochemistry with FFPE samples

• Epitope recognition: The antibody recognizes linear epitopes exposed after denaturation

• Buffer considerations: Strong lysis buffers containing SDS, heat treatment, reducing agents

• Advantages: Often provides higher sensitivity for protein detection

• Limitations: Loss of conformational epitopes and protein interactions

Critical considerations for experimental design:

• An antibody validated for Western blotting may fail in applications requiring native protein (and vice versa)

• Validation must be performed for each specific application and condition

• For comprehensive studies, consider using multiple antibodies targeting different epitopes

The mismatch between conditions is a frequent cause of immunoassay failure—for example, when an antibody developed against denatured protein (typical for Western blots) is used to detect native protein in serum samples .

What are the known challenges in detecting low-abundance proteins like YMR001C-A in yeast systems?

Detecting low-abundance proteins like YMR001C-A in yeast presents several technical challenges:

Signal-to-noise ratio limitations:

• Hypothetical proteins like YMR001C-A often have low expression levels

• Non-specific binding can easily overwhelm true signal

• Solution: Implement rigorous validation and optimize antibody concentration

Sample preparation challenges:

• Cell wall interference: Yeast cell walls can limit accessibility to target proteins

• Recommendation: Optimize spheroplast preparation using zymolyase or enzymatic digestion

• For subcellular localization studies, use gentle fractionation protocols to preserve protein compartmentalization

Technical approaches to improve detection:

• Protein enrichment techniques:

  • TAP-tagging of YMR001C-A for affinity purification

  • Subcellular fractionation to concentrate proteins from relevant compartments

  • Immunoprecipitation prior to Western blotting

• Signal amplification methods:

  • Chemiluminescent substrates with extended reaction times

  • Tyramide signal amplification for immunohistochemistry

  • Multi-epitope detection (using multiple antibodies against different regions)

• Genetic modifications:

  • Overexpression systems to increase target abundance

  • Epitope tagging at the endogenous locus (maintaining native expression levels)

  • Note: Expression changes may affect biological relevance of findings

How does epitope selection influence the reliability of YMR001C-A Antibody in different experimental contexts?

Epitope selection is a critical determinant of antibody performance across experimental contexts:

Epitope accessibility considerations:

• Linear vs. conformational epitopes: Linear epitopes are more reliable for Western blotting but may be inaccessible in native conditions

• Transmembrane domains: Antibodies targeting these regions often perform poorly in solution-based assays

• Post-translational modifications: These can block epitope recognition if they occur at or near the binding site

Epitope conservation analysis:

• For cross-species studies, target highly conserved epitopes

• For strain-specific detection, target unique sequence regions

• Bioinformatic analysis should precede epitope selection to avoid crossreactivity with homologous proteins

Strategic epitope selection for specific applications:

• For Western blotting: Target hydrophilic regions, avoid transmembrane domains

• For immunoprecipitation: Target surface-exposed regions in native conformation

• For fixed tissue detection: Consider epitope masking by fixatives like formaldehyde

Multiple epitope targeting strategy:
Using antibodies against different epitopes of YMR001C-A provides:

• Validation through independent antibody approach

• Comprehensive protein detection regardless of modifications

• Ability to distinguish between protein isoforms or fragments

What is the optimal protocol for using YMR001C-A Antibody in Western blotting with yeast lysates?

Optimized Western Blotting Protocol for YMR001C-A Detection:

Sample preparation:

• Culture yeast cells to mid-log phase (OD₆₀₀ = 0.6-0.8)

• Harvest cells by centrifugation (3,000 × g, 5 minutes, 4°C)

• Lyse cells using one of two recommended methods:

  • Glass bead lysis: Resuspend in RIPA buffer with protease inhibitors, vortex with glass beads (5 × 1 minute cycles with cooling)

  • Enzymatic lysis: Treat with zymolyase to create spheroplasts before gentle lysis with detergent

• Clear lysate by centrifugation (14,000 × g, 15 minutes, 4°C)

• Quantify protein concentration using Bradford or BCA assay

Gel electrophoresis and transfer:

• Load 20-50 μg total protein per lane

• Include positive control (wild-type yeast) and negative control (YMR001C-A knockout)

• Separate proteins on 12-15% SDS-PAGE (optimal for low molecular weight proteins)

• Transfer to PVDF membrane (better for low abundance proteins than nitrocellulose)

• Transfer conditions: 100V for 1 hour or 30V overnight at 4°C

Immunodetection:

• Block membrane with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Incubate with primary YMR001C-A antibody (1:500-1:1000 dilution) overnight at 4°C

• Wash 4 × 5 minutes with TBST

• Incubate with appropriate HRP-conjugated secondary antibody (1:5000) for 1 hour at room temperature

• Wash 4 × 5 minutes with TBST

• Develop using enhanced chemiluminescence substrate

Optimization considerations:

• For enhanced sensitivity, consider using fluorescently-labeled secondary antibodies

• If non-specific bands appear, increase blocking time and optimize antibody concentration

• Incubating primary antibody in blocking solution containing 0.1% Tween-20 may reduce background

• For reproducible results, standardize lysate preparation method across experiments

How can I optimize immunoprecipitation protocols using YMR001C-A Antibody for protein interaction studies?

Optimized Immunoprecipitation Protocol for YMR001C-A:

Pre-immunoprecipitation considerations:

• Verify antibody suitability for IP (not all antibodies that work in Western blot work in IP)

• Determine optimal lysis conditions:

  • For identifying stable interactions: RIPA buffer (moderate stringency)

  • For capturing transient interactions: Gentler buffers like NP-40 (lower stringency)

  • Include protease and phosphatase inhibitors freshly before use

Step-by-step protocol:

1. Sample preparation:

• Start with 10⁷-10⁸ yeast cells in mid-log phase

• Harvest and wash cells in cold PBS

• Lyse cells using glass bead disruption in appropriate buffer

• Clear lysate by centrifugation (14,000 × g, 15 minutes, 4°C)

• Measure protein concentration

2. Pre-clearing (reduces non-specific binding):

• Incubate lysate with Protein A/G beads for 1 hour at 4°C

• Remove beads by centrifugation

• Transfer supernatant to new tube

3. Immunoprecipitation:

• Direct method:

  • Add 2-5 μg YMR001C-A antibody to lysate

  • Incubate with rotation overnight at 4°C

  • Add 50 μl Protein A/G beads, incubate 2-4 hours at 4°C

• Indirect method:

  • Pre-couple antibody to Protein A/G beads for 2 hours

  • Wash unbound antibody

  • Add beads to lysate, incubate overnight at 4°C

4. Washing:

• Wash beads 4-5 times with lysis buffer

• For final wash, use buffer with reduced detergent

• Remove wash buffer completely before elution

5. Elution options:

• Denaturing: Add SDS sample buffer and boil

• Native: Use peptide competition or pH elution if protein activity must be preserved

Analysis of immunoprecipitated complexes:

• For protein identification: Mass spectrometry analysis

• For confirmation of known interactions: Western blot

• For RNA-protein interactions: RT-PCR of co-precipitated RNA

Critical controls:

• IgG control: Perform parallel IP with non-specific IgG

• Input control: Save aliquot of pre-IP lysate

• Knockout control: Use YMR001C-A knockout strain as negative control

What troubleshooting strategies should I implement when facing non-specific binding issues with YMR001C-A Antibody?

Comprehensive Troubleshooting Guide for Non-Specific Binding:

Non-specific binding is a common challenge when working with antibodies against yeast proteins like YMR001C-A. The following systematic approach will help identify and resolve these issues:

1. Evaluate antibody quality and validation:

• Verify antibody validation data (genetic knockout controls, independent antibody confirmation)

• Check lot-to-lot variations by requesting validation data specific to your antibody lot

• Consider switching to a different antibody or using monoclonal antibodies for higher specificity

2. Optimize blocking conditions:

• Test different blocking agents:

  • BSA (1-5%): Good for phosphoprotein detection

  • Non-fat milk (3-5%): Effective for most applications but contains phosphoproteins

  • Commercial blocking buffers: Often provide lower background

• Extend blocking time (1-2 hours at room temperature or overnight at 4°C)

3. Adjust antibody conditions:

• Titrate primary antibody concentration (perform a dilution series)

• Reduce incubation temperature (4°C instead of room temperature)

• Add 0.1-0.3% Tween-20 to antibody dilution buffer

• Consider overnight incubation at 4°C with more dilute antibody

4. Modify washing procedures:

• Increase number of washes (5-6 washes instead of 3-4)

• Extend wash duration (10 minutes per wash)

• Use higher stringency wash buffers (increase salt concentration to 250-500 mM)

• For Western blots, use TBST instead of PBST for phosphoprotein detection

5. Sample preparation refinements:

• Freshly prepare lysates with complete protease inhibitor cocktails

• For yeast samples, optimize cell lysis methods to reduce background:

  • Compare mechanical (glass beads) vs. enzymatic (zymolyase) lysis

  • Centrifuge lysates at higher speed to remove particulates

• Pre-clear lysates with Protein A/G beads before immunoprecipitation

6. Technique-specific troubleshooting:

7. Add competitive inhibitors to reduce non-specific interactions:

• Include 0.1-0.5% non-ionic detergents (Triton X-100, NP-40)

• Add carrier proteins (0.1-1% BSA or gelatin)

• For yeast applications, add 0.1-1% yeast tRNA to block nucleic acid interactions

How can I design a comprehensive epitope mapping strategy for YMR001C-A Antibody?

Strategic Epitope Mapping for YMR001C-A Antibody:

Epitope mapping is crucial for understanding antibody specificity and optimizing experimental conditions. The following comprehensive approach combines computational prediction with experimental validation:

1. In silico prediction approaches:

• Sequence-based analysis:

  • Identify hydrophilic, surface-exposed regions using Kyte-Doolittle plots

  • Predict secondary structures using tools like PSIPRED

  • Analyze potential post-translational modification sites that might affect binding

  • Compare with homologous proteins to identify unique vs. conserved regions

• Structure-based prediction:

  • If 3D structure is available or can be modeled, use molecular docking

  • Predict surface accessibility of residues

  • Identify potential conformational epitopes

2. Experimental mapping strategies:

Peptide Array Mapping:

• Synthesize overlapping peptides (15-20 amino acids with 5-10 residue overlap) covering YMR001C-A sequence

• Spot peptides onto membranes or use pre-made peptide arrays

• Probe with YMR001C-A antibody

• Identify reactive peptides through colorimetric or fluorescent detection

• Narrow down to minimal epitope by synthesizing shorter overlapping peptides

Mutagenesis-Based Mapping:

• Create point mutations or small deletions in YMR001C-A sequence

• Express mutant proteins in yeast

• Test antibody binding using Western blot or immunoprecipitation

• Alanine scanning mutagenesis is particularly effective for identifying critical binding residues

Proteolytic Fragmentation:

• Digest native or recombinant YMR001C-A with various proteases

• Identify antibody-reactive fragments by Western blot

• Sequence reactive fragments by mass spectrometry

• This approach is especially useful for conformational epitopes

3. Validation of mapped epitopes:

• Test synthetic peptides for ability to block antibody binding

• Create recombinant fragments containing identified epitope

• Compare binding characteristics in different applications (Western blot, IP, etc.)

• Assess epitope conservation across yeast strains if cross-reactivity is desired

4. Applications of epitope mapping results:

• Design better immunogens for generating improved antibodies

• Develop blocking peptides to serve as specificity controls

• Predict conditions that might mask or denature the epitope

• Understand potential cross-reactivity with other proteins

5. Technical considerations for yeast proteins:

• Codon optimization may be necessary when expressing yeast protein fragments in E. coli

• Include proper controls when working with hypothetical proteins like YMR001C-A

• Consider testing epitope accessibility in different yeast compartments if subcellular localization is unknown

Citation and Documentation

Critical Evaluation Framework for YMR001C-A Antibody Sources:

When selecting between commercial sources of YMR001C-A antibody, researchers should systematically evaluate the following factors:

1. Validation comprehensiveness:

• Number of validation pillars employed (genetic, orthogonal, independent antibody)

• Relevance of validation to your intended application

• Validation in yeast strains similar to your experimental system

• Availability of raw validation data rather than cropped images

2. Technical specifications comparison:

3. Application-specific performance data:

• Examine provided images for each application

• Check signal-to-noise ratio in validation data

• Verify detection of endogenous (not just overexpressed) protein

• Confirm successful use in your specific application (WB, IP, etc.)

4. Cross-reactivity information:

• Review tested cross-reactivity with related yeast proteins

• Assess cross-species reactivity if relevant to your research

• Check for documented non-specific binding issues

5. Production and quality control:

• Manufacturing consistency between lots

• QC metrics provided for each lot

• Recombinant vs. animal-derived antibodies (recombinant offers better reproducibility)

• Documented stability data and shelf-life information

6. Supplier scientific support:

• Availability of technical specialists familiar with yeast applications

• Responsiveness to technical inquiries

• Provision of detailed protocols specific to YMR001C-A

• Willingness to share additional validation data upon request

7. Scientific literature presence:

• Citations in peer-reviewed publications

• Performance in independent antibody validation studies

• User reviews and feedback in antibody validation databases

• Commercial antibody scoring systems (e.g., Antibodypedia scores)

8. Practical considerations:

• Cost-effectiveness for your application volume

• Shipping conditions and stability during transit

• Return policy for non-performing antibodies

• Available formats and sizes to match experimental needs